Eris Lifesciences Limited has informed the Exchange regarding a press release dated August 25, 2025, titled "Eris Lifesciences Receives ANVISA approval at its Ahmedabad campus".
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.8 pts more than Nifty Smallcap 250 and 1.1 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Eris Lifesciences has received approval from ANVISA, Brazil's national health regulatory agency, for a manufacturing unit at its Ahmedabad campus. The approval follows a successful inspection by the agency in May 2025 and opens the door for Eris to enter Brazil, described as the largest pharmaceutical market in South America. The company said this endorsement from a stringent regulatory authority validates its GMP and quality systems. Eris reported FY25 revenue of INR 2,894 crore and annual branded formulations revenue of over INR 3,000 crore, with revenue and operating profit growing 2.6x over the last five years.
This is a positive milestone as it clears a key regulatory hurdle for international expansion into a large and lucrative market, potentially opening a new growth avenue beyond India. For shareholders, it strengthens the long-term growth story, though actual revenue contribution from Brazil will depend on subsequent product registrations and commercial launches.